NEW YORK (GenomeWeb) ­– The Atlantic Cancer Research Institute has agreed to license extracellular vesicle (EV) isolation technology to BioVendor – Laboratorní Medicína, a Czech biotechnology company developing in vitro diagnostics and research-use-only immunoassays.

The agreement gives BioVendor non-exclusive rights to use ACRI's Vn96 synthetic peptide for isolation of EVs to diagnose disease via liquid biopsy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.